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Histone deacetylase inhibitors impairs antibacterial defenses 
of macrophages 
Rapport de synthèse 
Les déacetylases d'histones (HDACs) déacétylent non seulement les histones, ce 
qui a généralement pour effet d'augmenter la transcription et l'expression génique, 
mais également d'autres protéines comme par exemple des protéines de choc 
thermique (HSP90), la tubuline alpha, certains récepteurs aux stéroïdes ainsi que de 
nombreux facteurs de transcription (NF-kB p65, Sp1, etc.). Ainsi les HDACs 
participent au contrôle de nombreux processus cellulaires. 
Les inhibiteurs des HDACs (ou HDACi), de part leur capacité à induire la 
différenciation cellulaire et l'apoptose, sont parmi les anti-cancéreux les plus 
prometteurs en cours de développement pour dans le traitement des néoplasies 
solides et hématologiques. Récemment, l'activité anti-inflammatoire et immuno-
modulatrice des HDACi a été mise en évidence et exploitée avec succès pour le 
traitement de pathologies auto-immunes dans des modèles précliniques. 
L'effet des HDACi sur la réponse immunitaire innée restant largement inconnu, nous 
avons entrepris la première étude d'envergure dans ce domaine. Dans un premier 
article, nous démontrons que les HDACi inhibent l'expression de nombreux gènes 
(récepteurs aux produits microbiens, cytokines, chimiokines, molécules d'adhésion et 
co-stimulatrices, facteurs de croissance, etc.) impliqués dans les défenses anti-
infectieuses in vitro. En accord avec ces données, les HDACi augmentent la 
mortalité d'animaux infectés dans des modèles de pneumonie et de candidose 
bénignes. De manière congruente, les HDACi protègent les animaux de mortalité 
induite par choc toxique et septique en inhibant la réponse inflammatoire exubérante 
qui caractérise ces pathologies (Roger T. et al., Blood 2011 ). 
Afin de caractériser plus en détails l'influence des HDACi sur la réponse immunitaire 
innée, nous avons également analysé l'impact de deux HDACi, l'acide valproïque 
(VPA) et la trichostatin A (TSA), sur les principaux mécanismes de défenses 
antimicrobiennes des macrophages. Dans un second article (Mombelli et al., Journal 
of lnfectious Diseases 2011 ), nous rapportons que la VPA et la TSA diminuent la 
capacité des macrophages à phagocyter et à détruire les bactéries Gram-positives 
Staphy/ococcus aureus et Gram-négatives Escherichia coti. En accord avec ces 
données, les HDACi inhibent l'expression de molécules impliquées dans la 
phagocytose comme les récepteurs éboueurs (Msr 1 et CD14) et de type lectine 
(Dectin 1 ), ainsi que les récepteurs aux opsonines (intégrines). Par ailleurs, les 
HDACi interfèrent avec l'expression de différentes sous unités de la NADPH oxydase 
(gp91phox, p22 phox, p47 phox, p40 phox, p67 phox et Rac2) et de l'oxyde nitrique (NO) 
synthétase inductible (iNOS), qui sont responsables de la production de dérivés 
oxygénés (ROS) et nitrogénés (NO) essentiels à la destruction des microorganismes 
dans le phagolysosome. En résumé, cette étude décrit des mécanismes par lesquels 
les HDACi diminuent la capacité d'ingérer et de détruire les bactéries, et ainsi 
augmentent la susceptibilité aux infections. 
Globalement, nos données indiquent que les HDACi sont de puissants anti-
inflammatoires qui pourraient favoriser la survenue d'infections chez les patients 
cancéreux traités avec ces drogues, comme semble par ailleurs le suggérer des 
études cliniques rapportées dans la littérature. Nous proposons un suivi clinique 
infectieux strict chez les patients traités avec ces agents. 
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Histone deacetylase inhibitors impair innate immune responses to Toll-like 
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Regulated by histone acetyltransferases 
and deacetylases (HDACs), histone acety-
lation is a key epigenetic mechanism con-
trolling chromatin structure, DNA accessi-
bility, and gene expression. HDAC 
inhibitors induce growth arrest, differen-
tiation, and apoptosis of tumor cells and 
are used as anticancer agents. Here we 
describe the effects of HDAC inhibitors 
on microbial sensing by macrophages 
and dendritic cells in vitro and host de-
fenses against infection in vivo. HDAC 
inhibitors down-regulated the expression 
of numerous host defense genes, includ-
ing pattern recognition receptors, ki-
nases, transcription regulators, cyto-
kines, chemokines, growth factors, and 
costimulatory molecules as assessed 
by genome-wide microarray analyses or 
innate immune responses of macro-
phages and dendritic cells stimulated with 
Toll-like receptor agonists. HDAC inhibi-
tors induced the expression of Mi-213 and 
enhanced the DNA-binding activity of the 
Mi-2/NuRD complex that acts as a tran-
scriptional repressor of macrophage cyto-
kine production. ln vivo, HDAC inhibitors 
increased the susceptibility to bacterial 
and fungal infections but conferred pro-
tection against toxic and septic shock. 
Thus, these data identify an essential role 
for HDAC inhibitors in the regulation of 
the expression of innate immune genes 
and host defenses against microbial 
pathogens. (Blood. 2011 ;117(4):1205-1217) 
1 ntrod uction 
The innate immune system plays an essential raie in antimicrobial 
defenses. Detection of microbial pathogens is carried out by 
sentine! cells of the innate immune system that are located in 
tissues (macrophages and dendritic cells [DCs]) in close contact 
with the host's natural environment or that are rapidly recruited to 
the site of infection (neutrophils). Recognition of invasive patho-
gens by immune cells relies on their capacity to detect microbial- or 
pathogen-associated molecular patterns, such as endotoxin, pepti-
doglycan, lipopeptides, glucans or mannans, ftagellin, and nucleic 
acids. This process involves the coordinated actions of soluble and 
cellular molecules composing components of the complement 
system, acute phase proteins, and membrane-associated or intracel-
lular pattern-recognition molecules, including Toll-like receptors 
(TLRs), nucleotide-binding oligomerization domain-like receptors, 
retinoic acid-inducible gene I like receptors, C-type lectin recep-
tors, and scavenger receptors. Ligand-activated receptors trigger 
the mitogen-activated protein kinase, nuclear factor-KB (NF-1<B), 
and interferon-related factor (IRF) signal transduction pathways 
that induce the transcription and production of immune genes, 
including cytokines that are critical for the activation of innate and 
adaptive immunity. 1.2 
Chromatin structure plays a central role in regulating gene 
expression. Acetylation of histones is an essential epigenetic 
mechanism controlling chromatin structure, DNA accessibility for 
transcription factors, and gene expression. The net state of acetyla-
Submitted May 10, 2010; accepted October 7, 2010. Prepublished online as 
B/oodFirst Edition paper, October 18, 2010; DOi 10.1182/blood-2010-05-284711. 
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tion of the E amino groups of lysine residues of histones is regulated 
by the opposing actions of histone acetyltransferases and histone 
deacetylases (HDACs). Acetylation of histones relaxes the chroma-
tin structure promoting gene transcription, whereas deacetylation 
of histones compacts the chromatin structure favoring gene silenc-
ing. HDACs have been classified into 4 subclasses based on their 
homology with yeast HDACs, their subcellular localization, and 
their enzymatic activity.3 Beside histones, nonhistones proteins 
(such as a-tubulin, heat shock protein 90, steroid receptors, and 
regulators of nuclear import) are also modified by reversible 
acetylation.4·5 Therefore, histone acetyltransferases and HDACs 
affect diverse biologie functions, principally cell differentiation, 
growth, and survivaJ.6-8 
HDACs are at the center of great interest for 2 major reasons. 
First, dysregulated HDAC expression or activity has been Iinked to 
the pathogenesis of cancer and inftammatory and autoimmune 
diseases. Second, small-molecule inhibitors of class I, II, and IV 
HDACs have been shown to exhibit anticancer activity with good 
safety profiles notably in patients with hematologic malignancies. 
Thus, these drugs are among the most promising anticancer 
agents under development.6•8- 10 Here we analyzed the impact of 
HDAC inhibitors on gene expression profiles in macrophages 
and DCs in vitro and on the host response to bacteria and fungi 
in vivo. We found that HDAC inhibitors exerted profound inhibi-
tory effects on the host innate immune antimicrobial defense 
The publication costs of this article were defrayed in part by page charge 
payment. Therefore, and solely to indicate this tact, this article is hereby 
marked "advertisement" in accordance with 18 use section 1734. 
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response, down-regulating the expression of innate immune recep-
tors, interfering with transcriptome remodeling after stimulation 
with TLR agonists, and inhibiting the expression of key antimicro-
bial cytokines and access01y molecules in whole blood, macro-
phages, DCs, and splenocytes. Consistent with these immunosup-
pressive effects, HDAC inhibitors enhanced the susceptibility of 
mice to bacterial and fungal infections. Conversely, HDAC inhibi-
tors protected mice from septic shock. 
Methods 
Ethics statement 
Ali animal procedures were approved by the Office Vétérinaire du Canton 
de Vaud (authorizations 876.5, 876.6, and 877.5) and performed according 
to the institution guidelines for animal experiments. 
Mice, cells, and reagents 
Eight- to 12-week-old female BALB/c mice (Charles River Laboratories) 
were housed under specific pathogen-free conditions. Bone marrow 
derived macrophages (BMDMs), thioglycollate-elicited peritoneal macro-
phages, and RAW 264.7 macrophages (ATCC TIB-71) were cultured as 
previously described. 11 Bone marrow-derived DCs (BMDCs) were ob-
tained by culturing bone marrow cells in Iscove modified Dulbecco medium 
containing 10% fetal calf serum (FCS; Sigma-Aldrich), 50µ,M 2-mercapto-
ethanol, and granulocyte-macrophage colony-stimulating factor. Spleno-
cytes were cultured in RPMI medium containing 2mM L-glutamine and 
10% FCS and 50µ,M 2-mercaptoethanol. Human myeloid DCs (moDCs) 
were produced as described previously. 12 Human whole blood assay was 
perfonned as described previously. 13 
Cells were exposed to Salmonella 111i1111esota ultra pure lipopolysaccha-
ride (LPS; List Biologicals Laboratories), Pam3CSK4 (EMC Microcollec-
tions), CpG oligonucleotide (CpG ODN; Invivogen), taxie shock syndrome 
toxin-1 (Toxin Technology), staphylococcal enterotoxin B, concanavalin A 
(Sigma-Aldrich), or heat-inactivated Escherichia co/i 018 (E co/i), Staphy-
/ococcus aureus, and Candida albicans. Trichostatin A (TSA), suberoylani-
lide hydroxamic acid (SAHA), and valproic acid (VPA) were from 
Sigma-Aldrich. The concentrations of TSA and VPA used in vitro did not 
affect the viability ofBMDMs (> 85% cell recovery after 18 hours). Orfiril 
(Desitin Pharmaceuticals), a commercial injectable solution of sodium 
valproate, was used for in vivo experiments. 
Microarray analysis and quantitative real-time PCR 
For each experimental condition, 2 independent samples were processed in 
parallel. Low RNA input fluorescent linear amplification kit (Agilent 
Technologies) was used for cDNA synthesis and cRNA amplification. 
Experimental samples were labeled with cyanine 5-CTP, whereas a contrai 
Universal mouse RNA mixture (Stratagene) was labeled using cyanine 
3-CTP (PerkinElmer). Labeled cRNA was hybridized onto high-density 
oligonucleotide microarrays containing approximately 20 000 60-mer 
(Mause Development Oligo Microarray Kit, reference G4 l 20A, and Mause 
Oligo Microarray Kit, V2, reference G4 l 21B, Agilent Technologies). Slides 
were scanned using a Microarray Scanner G2565AA system (Agilent 
Technologies) at a resolution of 5 µ,m. For data analysis, local background-
subtracted signais were calculated using Feature Extraction software 
(Agilent Technologies, Version A6.1. l ). To ensure spot quality, features and 
their respective background, which were not uniform in pixel fluorescence 
intensity distribution in both channels, were flagged (nonuniformity outlier 
flagging algorithm). Data were imported in GeneSpring, Version 7.0 
(Agilent Technologies) and then normalized using both per spot (signal 
channel divided by the corresponding contrai channel and generation of 
log10 ratio) and per chip (to the 50th percentile). The microarray dataset has 
been deposited in the Gene Expression Omnibus database (GEO; National 
Center for Biotechnology Information; accession numbers GPL7291, 
GSE22409). 
Real-time polymerase chain reaction (RT-PCR) was performed with a 
7500 Fast Real-Time PCR System using the Power SYBR Green PCR 
Master Mix (Applied Biosystems) and primer pairs (supplemental Table 
4, available on the B/ood Web site; see the Supplemental Materials link at 
the top of the online article ). 14 Samples were tested in triplicates. A standard 
made of successive dilutions of a reference cDNA was processed in parallel. 
Gene-specific expression levels were assessed relative to the expression of 
glycera/dehyde-3-plwsphate dehydrogenase (GAPDH) and Hprt and re-
ported in arbitrary units. In selected experiments, standards consisted of 
serial dilutions of a plasmid containing the target gene. 
Cytokine measurements 
Tumor necrosis factor (TNF) and interleukin-6 (IL-6) concentrations were 
measured by bioassay, 15 IL-12p40, and interferon-'Y (IFN-'Y) by enzyme-
linked immunosorbent assay (ELISA; BD Biosciences), and a broad 
screening of cytokines and chemokines production was performed using the 
Luminex technology (Luminex Corporation).14 
Proliferation 
Splenocytes (1.5 X 105) were cultured for 48 hours in 96-well culture 
plates. Proliferation was monitored by measuring 3H-thymidine incorpora-
tion over 18 hours. 
Flow cytometry 
BMDCs were incubated with 2.4G2 monoclonal antibody (mAb) and 
mAbs (BD Biosciences) specific for mouse major histocompatibility class 
II (14-4-4S-fluorescein isothiocyanate), CD! le (HL3-phycoerythrin [PE]), 
and CD40 (3/23-biotin revealed with CyChrome-conjugated streptavidin; 
BD Biosciences). moDCs were incubated with the lineage Cocktail 
1 (fluorescein isothiocyanate-conjugated mAbs specific for CD3, CD14, 
CD16, CD19, CD20, and CD56) and mAbs specific for human CDllc 
(B-ly6-PE-Cy5), HLA-DR (L243-APC) and CD40 (5C3-PE), CD80 (L307.4-
PE), CD86 (FUN-1-PE), or CC-chemokine receptor 7 (CCR7; 3Dl2-PE). 12 Data 
were analyzed using FlowJo Version 8.5.3 software (TreeStar). 
Electrophoretic mobility shift assay 
A total of 2 µ,g of nuclear extracts was incubated for 15 minutes at room 
temperature with a radiolabeled consensus NF-1<B probe (Santa Cruz 
Biotechnology) and analyzed by electrophoretic mobility shift assay. 16 
Western blot analyses 
Cell lysates were electrophoresed through polyacrylamide gels and trans-
ferred onto nitrocellulose membranes. 14 Membranes were incubated with 
antibodies specific for phosphorylated (phospho )-extracellular signal-
regulated kinase (ERK)l/2, total-ERKl/2, phospho-p38, total-p38, phospho-
IRF3, (Cell Signaling Technology), c-jun, Mi2b (Santa Cruz Biotechnol-
ogy), SNF2j3/BRG1 (Millipore), IRF7 (Invitrogen), phospho-signal-
transducer and activator of transcription protein (STATI; BD Biosciences), 
and Œ-tubulin (Sigma-Aldrich), and then revealed with secondary horse-
radish peroxidase-conjugated goat antirabbit IgG and the ECL Western 
blotting analyses system (GE Healthcare ). Acid-soluble proteins were 
extracted and analyzed by Western blotting using antiacetylated histone 
H3 and H4 antibodies (Cell Signaling Technology). 13 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation analysis was performed using the ChIP 
assay kit (Millipore) using antiacetylated histone H4 (06-866, Upstate 
Biotechnology) or Mi2b (sc-11378X, Santa Cruz Biotechnology) rabbit 
polyclonal antisera and normal rab bit IgG (sc-2027, Santa Cruz Biotechnol-
ogy) as described previously. 13 Immunoprecipitated DNA was amplified by 
PCR using primers described in supplemental Table 4. 
siRNA silencing in RAW 264.7 mouse macrophages 
RAW 264.7 macrophages (6 X 104 cells per well) were seeded in 24-well 
plates and transfected the next day with 187.5 ng ofMi-2b or Brgl siRNA 
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duplexes or negative contrai (sequences available in supplemental Table 4) 
and HiPerFect transfection reagent (QIAGEN) according to manufacturer's 
instruction. After 3 days, cells were stimulated for 4 hours with 0 to 
10 ng/mL LPS. Gene expression was analyzed by real-time PCR. Mi-2b 
and Brg 1 mRNA levels were decreased by 60% in ce lis transfected with the 
specific siRNAs. 
ln vivo models 
Klebsiella pneumonia sepsis. A total of 10 CFU of a clinical isolate of 
K pneumoniae was injected intranasally into mice treated 15 minutes earlier 
with a single dose of valproate (Orfiril, 200 mg/kg intraperitoneally). 17 
Systemic candidiasis. Mice were challenged through the tail vein with 
1.2 X 105 CFU of a clinical isolate of C albicans. Valproate treatment 
(200 mg/kg intraperitoneally) was administrated 15 minutes before 
C albicans challenge and repeated daily during 24 days. 
Pm113CSK4-i11d11ced shock. Mice were injected with D-galactosamine 
(2 g/kg intraperitoneally) followed immediately after by Pam3CSK4 
(1.6 mg/kg intraperitoneally). 11 Valproate injections (200 mg/kg intraperito-
neally every 12 hours) were started 2 days before D-galactosamine injection 
and discontinued 48 hours after Pmn3CSK4 challenge. 
CLP. Animais were pretreated intraperitoneally 1 hour before cecal 
ligation and puncture (CLP) with valproate (200 mg/kg) and injected 
subcutaneously every 12 hours with gentamicin (! 0 mg/kg), clindamycin 
(30 mg/kg), and buprenorphine (0.1 mg/kg). 
Doses of valproate were selected based on previous publications and 
adjusted to the specific conditions of the sepsis models. 
Statistical analysis 
Comparisons among treatment groups were performed using the Fisher 
exact test for categorical data and the Mann-Whitney tests for continuous 
variables. The Kaplan-Meier method was used for survival, and differences 
were analyzed by the log-rank sum test. The analyses were performed using 
Prism software Version 5.03 (GraphPad). Ali reported P values are 2-sided, 
and values Jess than .05 were considered to indicate statistical significance. 
For microarray analyses, statistical significance of differentially expressed 
genes (2-fold changes) was evaluated by analysis of variance using the 
Benjamini and Hochberg false discovery rate correction (5% ). 
Results 
Inhibition of HDACs down-regulates the expression of innate 
immune genes in macrophages 
Transcriptome analyses. The transcriptome of BMDMs was 
examined using the Agilent high-density Mause Development 
Oligoarrays, which contained 20 280 unique 60-mer corresponding 
predominantly to expressed sequence tags and with the Mouse 
Oligo Microarray Kit (V2) containing 20 156 indexed gene probes. 
At baseline, TSA (t = 4 hours of incubation), a prototypical 
broad-spectrum inhibitor of class I, Il, and IV HDACs, modified 
the expression of 1594 macrophage genes (7.7% of the transcrip-
tome), of which 772 (3.6%) were found to be down-regulated and 
822 (4.1 %) up-regulated. HDAC inhibitors significantly reduced 
the expression of numerous pattern recognition molecules and 
immune receptors involved in the sensing of a broad range of 
microbial products, including bacterial Iipopeptides, lipoteichoic 
acid, peptidoglycan, endotoxin, fiagellin, viral nucleic acids, and 
fungal 1)-glucan (supplemental Table 1). We then performed 
lime-course analyses of gene expression profiles of BMDMs 
preincubated for 1 hour with TSA before stimulation for 1, 2, 4, and 
20 hours with TLR1/TLR2 (Pam3CSKi Iipopeptide) or with TLR4 
(LPS) agonists (Figure IA-B). TSA inhibited the up-regulation of 
32% to 58% and 33% to 60% of the genes induced by LPS or 
Pam3CSK4, respectively. Conversely, TSA counter-regulated the 
down-regulation of 60% to 73% and 51 % to 75% of the genes 
repressed by LPS or Pain3CSKi. In contrast, TSA potentiated the 
effects of LPS and Pam3CSK4 on only a small proportion of genes 
(2%-16%). The genes modulated by TSAincluded signal transduc-
tion, immunoregulation, cytoskeleton and cell structure, metabo-
lism and cell cycle, growth, and apoptosis (complete listing of the 
genes: Figure lC-D, supplemental Tables 2-3). 
We then focused our analyses on innate immune gene families 
known to play a critical role in the host antimicrobial defense 
response. TSA exerted prominent inhibitory effects on LPS- or 
Pam3CSKi-induced genes (Figure lC-D). Indeed, TSA inhibited 
LPS- and/or Pam3CSI<.i-induced up-regulation of genes encoding 
for molecules involved in the sensing of microbial compounds, 
such as Tirs, Cdl4, Md-2, scavenger receptors (Scarb2), cytosolic 
microbial sensors (Aiml, Mda-5, Nlrp3, Nodl, Nod2, Eif2ak2/Pkr, 
Pycard/Asc, Mevf/Pyrin, and RlG-I), c-type lectins (Clecs and 
Msrl), formyl peptide receptors (Fprs), IgE and IgG Fe receptors, 
complement and complement receptors (Clqa, Clr, and Cfb/H2-
Bf), and adhesion molecules (Icaml, integrins, and Vcaml; Table 
1). The effect of TSA on the expression of Tirs, Cdl4, Cd36, and 
Md-2 was confirmed by real-time PCR (Figure lE). TSA also 
inhibited the expression of adaptor molecules (MyD88 and Ti-
cam2), kinases (Iraks, Jaks, Lck, Map3ks, Ripk2, Syk, Tank, Tbkl, 
and Trafl), phosphatases, and transcription modulators (Atfs, 
Cebps, Irfs, Junb, Nfkbs, Spic, Stats, and Socs!; Table 1). In 
addition, TSA down-regulated a wide range of LPS- and/or 
Pam3CSK4-stimulated mediators involved in chemotaxis, inflamma-
tion, tissue repair, and antigen processing and presentation. This list 
of genes included cytokines (Ilia, Illrn, 116, lll2a, Ill2b, I115, I118, 
l123a, 1127, Ltb, Tnf, Tnfaip3, Tnfsf4, and Tnfsf9), chemokines 
(Cc14, Ccl7-9, Ccl12, Ccll7, Ccl22, Ccl24, Cklfsf3, Cklfsf6, 
Cklfsf7, Cxc12, Cxcl5, Cxcl12, Cxcll6, and Cx3cll), growth 
factors (Csf2, Edn 1, and Tmpo ), and their receptors (Illrll, l12rg, 
l14ra, IllOrb, Ill3ral, Crlf3, Cxcll2, Cxcll6, Pdfrl, Tnfrsfla, 
Tnfrsf14, Ifnarl, Ifnar2, Ifngr2, Csf3r, and Ednrb), cathelicidin 
antimicrobial peptide (Calmp), matrix metalloproteinases, ubiquit-
ins, proteasome subunits and molecules involved in autophagy 
(Atg161), antigen transport (Tapl and Tap2), and peptide presenta-
tion (H-2D, H-2E, and H-2Q; Table 1). Therefore, TSA strongly 
affected transcriptome remodeling of BMDMs stimulated with 
microbial products exerting predominantly inhibitory effects, indi-
cating that acetylation of histones or nonhistone proteins is 
required for optimal transcription of a large number of macrophage 
genes involved in microbial sensing and host defenses. 
Cytokine production. To validate the observations generated 
from microarray profiling, we quantified the production of cyto-
kines (ie, TNF, IL-6, and IL-12p40) in BMDMs exposed to LPS, 
Pam3CSKi, E coli, or S aureus. Real-time PCR analyses (Figure 
2A), bioassay, and ELISA measurements (Figure 2B-C) confitmed 
that TSA strongly inhibited TNF, IL-6, and IL- l 2p40 production in 
a time- and dose-dependent manner. Yet, TSA did not inhibit 
LPS-induced Tnf mRNA and protein (Figure 2A-B). Similar results 
were obtained in thioglycolate-elicited peritoneal macrophages 
(data not shown). 
To confirm the findings obtained with TSA, we tested the effects 
of 2 other HDAC inhibitors: SAHA, a hydroxamate, and VPA, a 
short chain fatty acid. Like TSA, SAHA and VPA used at clinically 
relevant concentrations (4-lOOnM and 4-100µ,M) dose-
dependently inhibited TNF, IL-6, and IL-12p40 production in 
BMDMs stimulated with Pam3CSKi (Figure 2D). VPA also mru~edly 
reduced (up to 50-fold) the production of 13 of 15 mediators 
induced by LPS or Pam3CSK4 in whole blood (Figure 2 E-F). 
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Figure 1. Trichostatin A inhibits the expression of innate immune genes in macrophages. BMDMs were preincubated for 1 hour wi th or without TSA (1 OOnM) before 
exposure (C-D, 4 hours) to LPS (100 ng/mL) or Pam3CSK, (100 ng/mL) . Transcriptome was analyzed with Agilent Mouse Development Oligoarrays (A-B) or Mouse Ohgo 
Microarray Kit V2 (C-0). (A) Number of genes either up-regulated or down-regulated by LPS and Pam, CSK, without preincubation wi th TSA (folr:f change > 2 vs medium). 
(B) Effect of 1-hour preincubalion with TSA on genes (expressed in percentage) either up-regulated or down-regulated by LPS or Pam3CSK, (fold change > 2 vs medium). 
White represents no change; red, inhibition; and green, increase by TSA compared with stimulation with LPS or Pam,CSK. alone. (C) Heal map of selected pattern recognition 
molecules (medium, TSA, LPS and Pam3CSK4 : 4 hours of incubation, LPS + TSA and Pam3CSK4 + TSA; 1-hour preincubation with TSA followed by 4-hour incubation w1th 
LPS and Pam3CSK,). (D) Effect of 1-hour preincubation with TSA (fold changes were calcu lated vs LPS or Pam,CSK4 alone) on a selection of genes up-regulated by LPS or 
Pam,CSK, and grouped into various categories based on their biologie functions (microbial sensing and killing; adhesion; cytokine, growth factor and receptors; signaling; 
antigen processing and presentation). White represents no change; red, inhibition; and green, increase by TSA compared with stimulation with LPS or Pam,CSK, alone. 
(E) Tlr1 -9, Md-2, Cd14, and Cd36 mRNA copy number was determined by RT-PCR and expressed relative to that of GAPDH. Data are representative of 2 independent 
experiments. 
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Table 1. Selection of genes whose up-regulation by LPS or Pam3CSK.i is inhibited by TSA in BMDMs 
Adhesion 
molecule 
Afcam 
Cd47 
/caml 
/lga4 
ftga5 
ftgal 
ftgax 
/lgb3 
Vcaml 
lnnate 
receptor 
Aiml 
Birc (c/AP2) 
Card4 (Nod!) 
Carc15 (Nod2) 
Cd14 
Ciasl (Nfrp3) 
C/ec2d 
C/ec4a2 
C/ec4d 
Clec4e 
Eif2ak2 (Pkr) 
Fcerlg 
Fcgr2b 
Frpl 
Fpr-rs2 
lfihl (Mda5) 
Ly96(Md-2} 
Mefv (Pyrin) 
Msrl 
Pycard 
Scarb2 
Ddx58 (RIG·f) 
Tfrl 
Tfr2 
Tfr3 
T/r6 
Tfrl 
Tfr9 
Signal 
transduction 
Csnklal 
frak2 
frak3 
Jakl 
Jak2 
Lck 
Map3klip2 
Map3k8 (Tp/2) 
Mapkapk2 
Myd88 
Piast 
Prkr 
Plk2 
Ripk2 
Socsl 
Stk19 
Syk 
Tank 
Tbkl 
Ticam2 
Tra fi 
Trim30 
Phosphata se 
Duspl (Mkp-1) 
Dusp4 
Dusp16 
Ptpn6 
Ptpn9 
Ptpn12 
Transcription 
regulator 
Atf3 
Atf4 
At15 
Bat! 
Bc/3 
Belle 
Bc/10 
Cebpb 
Cebpd 
Cited2 
Hmgb2 
fkbke 
lrfl 
lrf2 
/rf5 
frfl 
Junb 
K/16 
Nfkbl 
Nfkb2 
Nfkbib 
Nfkbie 
Nfkbiz 
Piast 
Rel 
Re/a 
Relb 
Spic 
Stat3 
Cytokine, 
chemokine, 
and growth 
factor 
Cc/4 
Cc/7 
Cc/8 
Cc/9 
Cc/12 
Cc/17 
Cc/22 
Cc/24 
Ccr/2 
Csf2 
Cklfsf3 
Cksls6 
Ck/fsfl 
Cxc/2 
Cxc/5 
Cxc/12 
Cxc/16 
Cx3cf1 
Ednl 
ffla 
fflrn 
ff6 
ff12a 
ff12b 
ff13ra1 
1115 
1118 
1123a 
1127 
Cytokine, 
chemokine, 
and growth 
factor receptor 
Ccr/2 
Cr/13 
Csl3r 
Ednrb 
ffnarl 
lfnar2 
ffngr2 
lllr/1 
ff2rg 
ff4ra 
fflOrb 
ff13ra1 
Pdfrf 
Ptafr 
Tnfrsfla 
Tnfrsf14 
Antigen 
processing 
and 
presentation 
Alg161 
C/sz 
H2-DMb1 
H2-Ea 
H2-Eb1 
H2·M3 
H2-010 
H2-07 
Psma3 
Psma4 
Psma5 
Psma6 
Psmbl 
Psmb8 
Psmb9 
PsmblO 
Psmel 
Psme2b 
Tapi 
Tap2 
Tapbp 
Tapbpl 
Ubiquiti-
nation 
Ubc 
Ubelf 
Ube2c 
Ube2d3 
Ube2e2 
Ube2j1 
Ube2j2 
Ube216 
Ube2m 
Ube2r2 
Ube2v1 
Ub/3 
Ubldl 
Ufml 
Usp12 
Usp18 
Usp24 
Usp42 
Others 
Cafmp 
Clqa 
Clr 
H2-Bf 
F10 
Mmp9 
Mmp14 
Mmp25 
Nos2 
Pde4b 
Pld2 
Plger4 
Piges 
Ptgir 
Plgs2 
Sod2 
Txnl 
Tnfrsf5 (Cd40) 
Stat5a fnhba 
HDAC inhibitors down-regulated the production of IL-lra and 
IL-10, suggesting that the reduced expression of proinflammatory 
cytokines was not the result of an increased expression of 
ant i-infl ammatory cytokines. 
Expression of IFNs and IFN-dependent genes. Together with 
cytokines and chemokines, type I interferons (IFN-cx and IFN-f3) 
are central mediators of innate and adaptive immune responses 
against viral and bacterial infections. 18•19 In response to LPS 
stimu lation, macrophages produce copious amounts of IFN-f3 that 
stimulates the transcription of Jfna , Cc/2 , Cc/8, Cc/12 , Cxc/10, and 
Nos2 (encoding for iNOS), lrfl, and lrj8.20•21 LPS, but not 
Pam3CSKi, induced rapid (1 hour) Ifnb mRNA expression and 
sustained IFN-f3 secretion by BMDMs, whereas LPS or Pam3CSKi 
induced early (2 l10urs and 4 hours, LPS) or late (8 l10urs and 
24 hours, Pam3CSK4) Ifna4 mRNA up-regulation (Figure 
3A-C). lnterestingly, TSA up-regulated and markedly prolonged 
(up to 24 l10urs) IFN-f3 mRNA and protein expression after LPS 
exposure (Figure 3A-B), confirming microarray data (supplemental 
Table 2). In contrast, it completely inhibited the up-regulation of 
Ifna4 mRNA (Figure 3C). TSA also inhibited the expression of 
LPS-induced Ccl8, Ccll2, CxcllO, Nos2, and Irf7 mRNA (Figure 
30) and of numerous other LPS-induced IFN-f3-dependent genes 
Llb 
Pbefl 
Tnf 
Tmpo 
Tnfaip3 (A20) 
Tnfsf4 (OX.40L) 
Tnfsf9 (4-IBBL) 
(supplemental Figure 1). Yet, TSA did not reduce LPS-induced 
Ccl2 and Irf8 mRNA and late (24 hours) IFN-[3-independent Ifna4 
mRNA (Pam3CSKi) and CclS mRNA (LPS and Pam3CSKi). Thus, 
the massive accumulation of IFN-f3 induced by TSA in BMDMs 
did not overcome its inhibition of IFN-f3-dependent gene expres-
sion. Of interest, TSA dose-dependently suppressed the prolifera-
tion of splenocytes induced by LPS , Pam3CSKi, CpG ODN, or 
E coti (Figure 3E). It also inhibited the release of IFN--y by 
splenocytes exposed to staphylococcal enterotoxin B, taxie shock 
syndrome toxin-1, or concanavalin A (Figure 3F). 
HDAC inhibitors impair the response of DCs 
We then examined the effects of HDAC inhibitors on innate 
immune responses of mouse BMDCs and human moDCs. TSA 
inhibited the production of cytokines (IL-6 and IL- l 2p40) and the 
up-regulation of CD40 by BMDCs stimulated with LPS , Pam3CSKi, 
CpG ODN, E coti , S aureus, or C atbicans (Figure 4A-D). 
Similarly, TSA and VPA inhibited proinflammatory and anti-
inflammatory cytokines (TNF, IL-lcx, IL-1[3, IL-lra, IL-6, IL-JO, 
IL-12p40, and IL-12p70), chemoki nes (IP-10/CXCLlO, MIP-lf3/ 
CCL4, MCP-l/CCL2, and RANTES/CCLS), IFN--y, G-CSF, and 
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Fi ure 2. HDAC inhibitors inhibit cytokine release by macrophages exposed to microbial products and bacteria. BMDMs were teincubated for 1 hour with or wi~hout TSA (1 OOnM unless specified) before exposure to LPS (1 OO ng/mL), Pam3CSK4 (1 OO ng/mL), and heat-k1lled E co/1 or S aureus (10 CFU/mL). (A-C) TNF, IL-6,_an~ 
IL-12 40 mRNA (A) and protein (B-C) production by BMDMs. TNF, IL-6, and IL-12p40 mRNA levels were an~ lyzed by RT-PCR, and results are expressed as the ratio o 
c okines to GAPDH mRNA levels. Data are representative of 3 independent experiments. Cytokine were quant1f1ed in cell culture supernatants collected af1er 8 h?urs (TNF) a~d 18 hours (IL-6 and IL-12p40). Data are mean :!: SD of triplicate samples tram one experiment representative of 3 independent expenments. A.U. 1nd1cates arb1trary urnts. 
(D) BMDMs were preincubated for 1 hour with or without SAHA (4, 20, and 100nM) or VPA (4, 20, and 100µM) before exposure to Pam3CSK, (100 n_gl ml). TNF, IL-6, and 
IL-12p40 were quantified in cell culture supernatants collected af1er 8 hours (TNF) and 18 hours (tl-6 and IL-12p40). Data are mean :!: SD of tnphcate samples f~~~ 
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Figure 3. HDAC inhibition enhances the production of IFN-jl. (A·D) RNA and cell culture supernatants were collected tram BMDMs preincubated for 1 hour with ( + ) or 
without (- ) TSA (1 OOnM) before exposure to LPS (1 OO ng/ml) or Pam3CSK4 (100 ng/ml). (A·B) IFN-p mRNA and protein expression was quantified by RT-PCR and ELISA. 
Results are expressed as the ratio of lfnb mRNA level to that of GAPDH. Data are mean :!: SD of triplicate samples from 1 experiment representative of 2 experiments. 
(C-D) ffna4 (C) , Ccl2, Ccl5, Cela, Ccl12, Cxcf10, Nos2, lr17, and lr18 (D) mRNA contents were quantified by RT-PCR. Results are expressed as the ratio of mRNA level of the 
gene of interest to that of GAPDH. Data are representative of 2 independent experiments. A.U. indicates arbitrary units. (E-F) Sp/enocytes were incubated with TSA and LPS 
(5 µg/ml) , Pam3CSK, (5 µg/ml), CpG ODN (CpG, 0.5µM), E coti (5 x 107 CFU/ml), staphylococcal enterotoxin B (SEB, 1 ·5 µg/ml) , taxie shock syndrome toxin-1 (TSST-1, 
0.4-2.0 µg/ml), and concanavalin A (5 µg/ml). (E) Pro/iferation was measured by 3H-thymidine incorporation. Data are mean :!: SD of tripficate samples and are 
representative of 2 independent experiments. (F) IFN-y production was quantified by ELISA in cell culture supernatants collected alter 48 hours. Data are representative of 2 
independent experiments. 
TGF-a production by moDCs in response to LPS stimulation 
(Figure 4E-F). TSA and VPA also inhibited the up-regulation 
induced by LPS of the costimulatory molecules CD40, CD80, and 
CD86 and of CCR7 (Figure 4G). These results suggested that 
HDAC inhibitors affect biologie activities ofDCs, playing a central 
role in orchestrating the innate and adaptive responses to infection. 
HDAC inhibitors increase the expression and the DNA binding 
of the transcriptional repressor Mi-213 
We then examined whether HDAC inhibitors affected signal 
transduction pathways in the macrophage (Figure 5). Neither 
ERKJ/2 or p38 phosphorylation nor NF-KB, c-j un, IRF3, or IRF7 
nuclear translocation was inhibited by TSA, VPA, or SAHA in 
BMDMs, peritoneal macrophages, or RAW 264.7 macrophages 
(Figure 5A-C; and data not shown). Consistent with the fact that it 
enhanced LPS-induced IFN-13 expression (Figure 3B), TSA mark-
edly prolonged STAT!a/13 phosphorylation (Figure 50). Thus, 
HDAC inhibitors did not inhibit mitogen-activated protein kinases, 
NF-KB , IRFs, and STATJ signal transduction pathways induced by 
microbial products in macrophages. 
Given that histone acetylation is associated with active gene 
transcription, we then analyzed by chromatin immunoprecipitation 
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Figure 4. HDAC inhibitors inhibit the response of DCs Io microbial stimulation. (A-C) BMDCs were preincubated for 1 hour wilh TSA before stimulation for 18 hours or the 
indicated lime with LPS (100 ngiml}, Pam3CSK4 (100 ng/ml}, CpG oligonucleotide (CpG, 0.7µM}, and heat-killed C albicans, E coti, or S aureus(107 CFU/ml}. (A-8) IL-6 and 
IL-12p40 production . Data are mean :!: SD of triplicate samples and are representative of 4 independent experiments. (C} Cd40 mRNA expression quantified by RT-PCR. 
Results are expressed as the ratio of Cd40 mRNA level to that of GAPDH. Data are mean :!: SD of 1 experiment representative of 3 independent experiments. AU indicates 
arbitrary units. (D} CD40 mean fluorescence intensity (MFI} determined by flow cytometry. Data are representative of 3 independent experiments. (E-G} Human moDCs were 
preincubated for 1 hour with TSA (E-F, 100nM} or VPA (E-F, 100µM} before exposure Io LPS (30 ng/ml} for 18 hours. (E} TNF and IL-6 production. Data are mean :!: SD of 
triplicate samples and are representative of 2 independent experiments. (F) Effect of TSA and VPA on cytokine and chemokine production by 2 independent preparations of 
moDCs. Mediators were analyzed using the Luminex technology ("Cytokine measurements"). + indicates inhibition (fold change > 2); and - , no effect. (G) CD40, CD80, 
CD86, and CCR7 expression analyzed by flow cytometry. Data are representative of 2 independent experiments. 
the extent of histone H4 acetylation of the Tnf and 116 promoters in 
BMDMs stimulated with LPS or Pam3CS~ (Figure 5E). TSA 
increased histone H4 acetylation of both promoters, suggesting that 
there was no correlation between the status of histone acetylation 
and the observed down-regulatory effect ofTSA on gene transcrip-
tion (Figure 2A). 
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(100nM unless specified) and exposed to LPS (100 ng/ml) or Pam3CSK4 (1 OO ng/ml) for the indicated lime or 1 hour (E). NF-KB DNA binding activity and NF-KB p65, c-jun, 
phosphorylated (P-) , and total ERK1 /2 and p38 and P-STAT1 expression were analyzed by electrophoretic mobility shift assay (A) and Western blot (B-D) using nuclear (nue) 
and cytosolic (cyto) extracts. The retarded complex detected by electrophoretic mobility shift assay was dose-dependently inhibited by cold wild-type but not mutant NF-KB 
oligonucleotide, and supershifted using anti-p65 antibody (data not shown) . Acetylation of histone H4 (E) and Mi-2[3 recruitment (1) Io Tnf and 116 promoters were analyzed by 
chromatin immunoprecipitation. Mi-2[3 and BRG1 mRNA and protein levels were quantified by real-time PCR (F) and Western blot (G) with densitometric analyses (H). Data are 
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incubated for 4 hours with ( + ) or without ( - ) 10 ngiml of LPS. 116 and Tnf mRNA levels were analyzed by RT-PCR and results expressed as the ratio of cytokine Io GAPDH 
mRNA levels. Data are representative of triplicate determinations from 1 experiment. 
The Mi-2/NuRD and SWI/SNF (also called BAF in mammals) 
ATP-dependent remodeling complexes play a central role in 
regulating gene expression.22 Mi-2f3 (CHD4) acts as a transcrip-
tional repressor, whereas BRG 1 (SMARCA4, the catalytic subunit 
of the BAF complex) acts as a transcriptional activator of 
secondary LPS-induced genes in 177.4 macrophages.23 Given that 
HDAC inhibitors impaired the expression of secondary (ie, l/6) but 
not primary (ie, Tnf) LPS-induced genes in BMDMs, we hypoth-
esized that TSA mediated its effects by affecting the expression of 
the Mi-2[3 and BRG 1 dyad. Interestingly, TSA markedly up-
regulated the expression of Mi-2f3 mRNA in BMDMs exposed to 
LPS and Pam3CSKi (Figure 5F). In constrast, TSA had a modest 
inhibitory effect on the expression of BRG 1. In line with these findings, 
TSA increased basal and LPS-induced Mi-2f3 protein expression 
(Figure 5G-H). Chromatin inmmnoprecipitation studies revealed that 
TSA sl.rongly increased Mi-2f3 recruitment to the Il6 promoter in 
BMDMs exposed to LPS, whereas it reduced the binding of Mi-2f3 to 
the Tnf promoter (Figw·e 51). siRNA-mediated silencing of Mi-2f3 in 
RA W 264.7 mouse macrophages greatly enhanced LPS-induced TI6 
mRNA expression without a significant effect on Tnf mRNA levels 
(Figure 51). Conversely, BRG 1 silencing only had a ve1y modes! effect 
on boù1 Il6 and Tnf mRNA expression. Altogether, these data suggest 
that TSA may inhibit cytokine production via an increased expression of 
the transctiptional repressor Mi-2f3 in macrophages. 
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Figure 6. HDAC inhibition increases mortality Io nonsevere infection 
with K pneumonia and C albicans. BALB/c mice were injected intraperi-
toneally with valproate (Orfiril, 200 mg/kg) or phosphate-buffered saline 
(PBS). (A) Peritoneal exudate cells and splenocytes were collected alter 
1 hour. Histone H4 acetylation (AcH4) was analyzed by Western blotting. 
(B-C) Mice were infected intranasally with 1 O CFU of K pneumoniae 
15 minutes alter valproate. (B) Circulating bacterial counts 3 days alter 
infection and (C) survival (n = 15 mice per treatment groups; P = .04 and 
.0004 for bacterial counts and survival, respectively). The dashed line 
represents the lower limit of detection. (D) Survival of BALB/c mice injected 
with 1 .2 X 105 CFU of C albicans and treated with valproate or PBS daily 
(n = 18 mice per treatment group; P = .02). 
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HDAC inhibitors impair innate immune responses in vivo 
We next investigated the effects of HDAC inhibitors in experimen-
tal models of bacterial and fungal sepsis or toxic shock titrated to 
cause either mild or severe infections or shock. We first verified that 
valproate enhanced the acetylation of histone H4 in vivo in 
peritoneal exudate cells and splenocytes (Figure 6A). In an 
otherwise nonsevere, acute K pneumoniae pneumonia mode!, 
valproate increased the proportion (53% vs 80%) and magnitude of 
bloodstream infections (Figure 6B; P = .04) and mortality (from 
6% to 60%, P = .0004; Figure 6C). Consistent with valproate-
induced impaired cytokine production by C albicans-infected 
BMDMs and BMDCs (Figure 4; and data not shown), valproate 
treatment was associated with accelerated (mean time to death: 
21.5 days vs > 40 days) and increased mortality (44% vs 75%, 
P = .02) in a model of chronic Candida infection (Figure 6D). 
Thus, inhibition of HDACs impairs host defenses in vivo, increas-
ing the susceptibility to and mortality of bacterial and fungal sepsis. 
Severe sepsis and septic shock are characterized by an early 
overwhelming inflammatory response to microbial invasion, and 
inhibition of proinflammatory mediators confers protection in 
sepsis models. 24·25 We therefore tested whether valproate might 
exert protective effects in models of fulminant toxic shock induced 
by Pam3CSI<.i or CLP. Administration of valproate caused a 2- to 
3-fold reduction of IL-6 and IL-12p40 circulating levels (Figure 
7A) and a notable increase in survival (0%-64%, P < .001) in the 
Pam3CSI<.i toxic shock mode! (Figure 7B). Similarly, valproate 
treatment increased survival from 17% to 42% (P = .04) in the 
CLP model (Figure 7C). 
Discussion 
These studies identify an essential role for acetylation of histones 
and nonhistone proteins in the regulation of inftammatory and 
innate immune gene expression, and in host defensive responses 
against microbes. Genome-wide microarray analyses revealed a 
critical role for HDACs in the expression of host defense genes, 
including pattern-recognition receptors, adaptor molecules, ki-
nases, transcription regulators, complement factors, cytokines, 
chemokines, and growth factors. HDAC inhibitors exert both 
immunosuppressive (a predominant effect) and immunostimula-
tory activities. Located at the forefront of the host defenses against 
microbial invasion, macrophages and DCs are an important source 
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Figure 7. HDAC inhibition protects !rom lethal toxic shock and severe sepsis. 
(A-8) BALB/c mice were injected intraperitoneally with valproate (Orfiril, 200 mg/kg 
started 2 days before and discontinued 2 days alter induction of shock) or PBS. 
Animais were sensitized with D-galactosamine and injected intraperitoneally with 
Pam3CSK4. (A) Plasma levels of IL-6 and IL-12p40 were determined 1 hour and 
3 hours alter challenge with Pam3CSK,. Data are mean :':: SD of 8 mice per treatment 
group. 'P < .001 for valproate versus PBS. (B) Survival of BALB/c mice subjected to 
Pam3CSK4-induced shock (n = 11 mice per treatment group; P = .001 ). (C) Survival 
of BALB/c mice subjected to CLP and treated with eîther valproate or PBS (every 
12 hours, starting 30 minutes alter surgery; n = 16-18 mice per treatment group). 
P= .04. 
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of cytokines. Inhibition of HDACs caused a marked reduction of 
cytokine and chemokine production induced by both cell types 
after exposure to TLR agonists. Of note, HDAC inhibitors also 
suppressed the release of IFN-œ and IFN-')' by macrophages and 
splenocytes. Likewise, TSA inhibited IFN-œ-stimulated gene acti-
vation and late IFN-13 induction by Sendai virus and doubled-
stranded RNA, and prevented IFN-œ-mediated inhibition of the 
cytopathic effects of vesicular stomatitis virus.26·27 Unexpectedly, 
we observed that HDAC inhibitors sustained LPS-induced IFN-13 
production in BMDMs. Nevertheless, the expression of numerous 
IFN-13/STATl-dependent genes was strongly inhibited by TSA and 
VPA, indicating that the increased production of IFN-13 did not 
overcome the potent inhibitory effects ofHDAC inhibitors. 
Phagocytes and professional antigen-presenting cells help bridge 
innate and adaptive immunity. Macrophages and DCs are key 
producers of IL-12 and IL-23 promoting the generation of protec-
tive Th l and Th 17 responses against intracellular and extracellular 
pathogens.28,29 HDAC inhibitors were found to be potent inhibitors 
ofIL-12 and IL-23 production by macrophages and DCs as well as 
CCR7, which is critical for the migration of DCs to secondary 
lymphoid organs (present data). 30-32 TSA inhibited the expression 
of several genes involved in antigen processing and presentation. 
Moreover, HDAC inhibitors have been reported to inhibit 
DC-stimulated allogeneic T-cell proliferation and Thl-cell activa-
tion32-34 and to block the differentiation of IL-17-producing 
T cells.35 Thus, inhibition of HDACs impacts on several key 
macrophages and DCs fonctions likely to affect the production of 
critical cytokines and the mounting of protective Th 1 and Thl 7 
immune responses. Of note, TSA did not inhibit TNF production by 
BMDMs and peritoneal macrophages stimulated with LPS. In 
contrast, TSA exerted potent inhibitory effects on whole blood, 
DCs, and BMDMs stimulated with microbial products other than 
LPS (Pam3CSI\:.i, E co/i, and S aureus). Similar results were 
obtained using SAHA and VPA. These observations suggest that 
HDAC inhibitors differentially affect gene expression according to 
the cell type or the stimulus studied. This could account for the 
discrepant effects of HDAC inhibitors on TNF production reported 
in the literature.30-33·36 Indeed, delaying TSA treatment until 1 hour 
after the addition of Pam3CSI<.i to BMDMs, or inhibiting protein 
synthesis at the time of preincubation with TSA, abrogated 
TSA-mediated inhibition of Pam3CSI<.i-induced TNF production. 
Thus, inhibition of stimulus-induced Tnf mRNA expression by TSA 
requires de novo protein synthesis, which cannot overcome a rapid 
induction of gene expression in BMDMs stimulated with LPS. 
HDAC inhibitors have been reported to interfere with the 
activation of the mitogen-activated protein kinases, IRFs, STATl, 
AP-1, or NF-1<B signal transduction pathways. However, these 
findings have been inconsistent and controversial.26·30·31 ·36·37 In 
BMDMs, we did not observe any impact of 3 HDAC inhibitors 
(TSA, VPA, and SAHA) on ERKl/2 or p38 phosphorylation or on 
NF-1<B, c-jun, IRF3, or IRF7 nuclear translocation induced by 
LPS or Pam3CSI<.i. Yet, we found that TSA markedly inhibited the 
recruitment of NF-1<B p65 and of RNA polymerase to the I16 
promoter (data not shown). This finding is consistent with the 
notion that acetylation of the NF-1<B subunits themselves or of 
molecules involved in the NF-1<B signal transduction pathway 
contrais the extent, potency, and duration of NF-1<B-mediated 
transcriptional activity.38 
Transcriptional repression mediated by HDAC inhibitors may 
also rely on acetylation-dependent recruitment of transcriptional 
corepressors or changes in chromatin architecture.38 In line with 
this hypothesis, we have previously shown that TSA inhibits the 
expression of the proinftammatory cytokine macrophage migration 
inhibitory factor via a local deacetylation of chromatin impairing 
the recruitment of the basal transcriptional machinery to the 
macrophage migration inhibitory factor promoter. 13·39 In the present 
study, we provide data suggesting that HDAC inhibitors induce the 
expression of Mi-213 and the activity of the Mi-2/NuRD complex, 
which acts as a transcriptional repressor of secondary LPS-induced 
cytokines, such as IL-6. Although little is known about the in vivo 
fonction of Mi-213, mice deficient in metastasis-associated protein 
2, a component of the Mi-2/NuRD complex, develop a lupus-like 
syndrome characterized by the hypersecretion of cytokines.40 
A main finding of our study is the fact that HDAC inhibitors 
impair the host natural defenses against microbial pathogens. 
Administration of valproate increased the susceptibility of mice to 
bacterial and fungal infections converting a nonsevere bacterial 
pneumonia into a highly lethal infection and markedly increasing 
the mortality of invasive candidiasis. Moreover, we have also 
observed that HDAC inhibitors reduced the expression of phago-
cytic receptors and phagocytosis and killing of bacteria by macro-
phages (M.M., J.L., T.C., T.R., manuscript in preparation). These 
results clearly demonstrate that the inhibitory effects of HDAC 
inhibitors on innate immune cells in vitro translate into robust 
immunosuppressive effects in vivo that negatively impact on the 
susceptibility to and outcome of infections. Severa! arguments led 
us to believe that these observations may have clinical implica-
tions. A vast amount of data indicate that interfering with critical 
mediators of innate or adaptive immunity (eg, TNF or IL-1) 
increases the risk of infections.41 Indeed, treatment of patients with 
TNF antagonists has been associated with an overall increased risk 
ofbacterial (tuberculosis, nontuberculous mycobacteriosis, listerio-
sis, and salmonellosis) and fungal (candidiasis) infections.42.43 
HDAC inhibitors are currently used for the treatment of hemato-
logic malignancies and solid tumors often in combination with 
other cancer or immune suppressive therapies increasing the risk of 
infection. In phase 1 and 2 clinical trials, patients treated with 
valproate, SAHA, MS-275, and ITF2357 have developed severe 
infections, even without neutropenia, that could be the result of the 
immune-suppressive activities of these HDAC inhibitors.44-49 These 
data suggest that monitoring of infections may be warranted in 
clinical trials of HDAC inhibitors. 
Taken advantage of their broad anti-inflammatory and immuno-
modulatory properties targeting several key mediators implicated 
in the pathogenesis of septic shock (such as TLRs, MyDSS, signal 
transducing molecules, and proinflammatory cytokines), we rea-
soned that HDAC inhibitors may prove to be beneficial as 
adjunctive therapy for septic shock. Consistent with this assump-
tion, valproate exhibited remarkable protective effects in a toxic 
shock mode! induced by Pam3CSI\:.i and in the CLP peritoneal 
sepsis mode!. In a recent fascinating article, Xu et al detected 
histones in the circulation of septic patients and baboons and 
. 1 . . 50 
showed that these proteins played a pathogemc ro e 111 sepsts. 
Purified histones H3 and H4 were found to be toxic for endothelial 
cells, to cause microvascular thrombosis, and to be lethal when 
injected intravenously into mice. Notably, antihistone H4 antibod-
ies rescued mice from lethal shock induced by LPS, TNF, or CLP. 
Given that histones appear to act as noxious danger-associated 
endogenous molecular patterns, one may wonder "".hethe1: ~he 
acetylation status of extracellular histones correlate~ wlth tox1c1t!. 
If so, deacetylation of histones released by necrottc and apopt1c 
cells could exert detoxifying and cytoprotective effects. 
Taken together, the present data identi~y protei~ acetylati~n as a 
key mechanism regulating the expression of important mnate 
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immune genes critically implicated in the sensing of and host 
responses to microbial pathogens. Inhibition of HDACs impairs 
essential biologie fonctions of innate immune cells, reducing their 
capacity to induce a proinftammatory response, to engulf and kill 
pathogens, and to mount an adaptive response increasing the 
susceptibility to infection. On the other hand, the broad anti-
inftammatory and immune-suppressive properties ofHDAC inhibi-
tors were found to be beneficial as adjunctive therapy for septic 
shock. Thus, these results suggest that the use of HDAC inhibitors 
as anticancer agents may increase the risk of infection and sepsis, 
whereas they may offer new therapeutic options for the manage-
ment of patients with septic shock. 
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Histone Deacetylase Inhibitors Impair 
Antibacterial Defenses of Macrophages 
Matteo Mombelli,1 Jérôme Lugrin,1 lvana Rubino,1 Anne-Laure Chanson,1 Marlyse Giddey,2 Thierry Calandra,1 and 
Thierry Roger1 
11nfectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne; and 2Department of 
Fundamental Microbiology, University of Lausanne, Switzerland 
Histone deacetylases (HDACs) control gene expression by deacetylating histones and nonhistone proteins. 
HDAC inhibitors (HDACi) are powerful anticancer drugs that exert anti-inflammatory and immunomod-
ulatory activities. We recently reported a proof-of-concept study demonstrating that HDACi increase 
susceptibility to bacterial infections in vivo. Yet, still little is known about the effects of HDACi on 
antimicrobial innate immune defenses. Here we show that HDACi belonging to different chemical classes 
inhibit at multiple levels the response of macrophages to bacterial infection. HDACi reduce the 
phagocytosis and the killing of Escherichia coli and Staphylococcus aureus by macrophages. In line with 
these findings, HDACi decrease the expression of phagocytic receptors and inhibit bacteria-induced 
production of reactive oxygen and nitrogen species by macrophages. Consistently, HDACi impair the 
expression of nicotinamide adenine dinucleotide phosphate (NAD PH) oxidase subunits and inducible nitric 
oxide synthase. These data indicate that HDACi have a strong impact on critical antimicrobial defense 
mechanisms in macrophages. 
The innate immune system plays a crucial role in host 
defenses against invasive microorganisms. Professional 
phagocytes are key sentinel cells of the innate immune 
system. Pathogen recognition relies on the capacity of 
phagocytes to sense microbial molecular motifs 
( eg, lipopolysaccharide, peptidoglycan, lipopeptides, 
mannans, glucans, flagellin, and nucleic acids) via pattern-
recognition receptors comprising Toll-like receptors 
(TLRs), nucleotide-binding oligomerization domainlike 
receptors (NLRs), retinoic acid-inducible gene I (RIG-I)-
like receptors (RLRs), C-type lectin receptors (CLRs), and 
scavenger receptors [l]. The engagement of phagocytic 
receptors, either through a direct interaction with 
Received 10 May 2011; accepted 24 June 2011. 
Correspondence: Thierry Roger, PhD, lnfectious Diseases Service, BH19-111, 
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, CH-1011 Lausanne, 
Switzerland (thierry.roger@chuv.ch). 
The Journal of lnfectious Diseases 2011;204:1367-74 
© The Author 2011. Published by Oxford University Press on behalf of the lnfectious 
Diseases Society of America. Ali rights reserved. For Permissions, please e-mail: 
journals.permissions@oup.com 
0022-1899 (print)/1537-6613 (online)/2011/2049-0010$14.00 
DOi: 1O.1093/infdis/jir553 
microbial motifs or through the recognition of opsonized 
infectious agents, stimulates the engulfment and the de-
livery of the pathogen to the phagosome, Phagosome 
maturation by fission and fusion with endosomes and 
lysosomes generates the phagolysosome that provides 
a powerful microbicidal microenvironment, usually re-
sulting in efficient microbial killing [ 2, 3]. The release of 
proinflammatory cytokines during an infection stimulates 
the production of powerful phagocyte activating mole-
cules like interferon y (IFNy), 
Reversible acetylation of the E amino groups oflysine 
residues from histones and nonhistone proteins (such as 
oHubulin, steroid receptors, HSP90, and regulators of 
nuclear import and transcription) is controlled by 
histone acetyltransferases and histone deacetylases 
(HDACs). Generally, acetylated histones are associated 
with active gene transcription, whereas deacetylated 
histones are associated with transcription repression 
[ 4-6]. The 18 mammal HD A Cs have been classified into 
class I (HDACl-3 and 8), class IIa (HDAC4, 5, 7 and 9), 
class IIb (HDAC6 and 10), class III (SIRTl-7), and class 
IV (HDACll) HDACs [4, 7]. Small-moleculeinhibitors 
of class I, II, and IV HDACs were originally identified 
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for their potential to induce cellular differentiation, growth ar-
rest, and apoptosis of transformed cells. HD A Ci targeting class I 
and II HDACs have been reported to counteract cancer de-
velopment by reducing tumor angiogenesis, metastasis, and 
invasion and antitumor immunity [ 4-6]. 
Besicles their anticancer properties, HDACi exert immuno-
modulatory activities that have been exploited for the treatment 
of inflammat01y and auto immune disease [ 8]. Recently, we re-
ported that HDACi interfere with the response of innate im-
mune cells stimulated with TLR agonists and increase the 
mortality of mice to microbial sepsis [9]. Yet, whether HDACi 
impair the phagocytosis and the killing ofbacteria by phagocytes 
remains unknown. To more deeply characterize the influence of 
HDACi on innate immune responses, we investigated whether 
HDACi have an impact on key antibacterial defense mechanisms 
of macrophages. We report that HDACi reduce the expression of 
phagocytic and opsonophagocytic receptors and inhibit the 
phagocytosis of Escherichia coli and Staphylococcus aureus, 2 of 
the most common infections agents, by macrophages. Moreover, 
HDACi impair the generation of reactive oxygen and nitrogen 
species by macrophages infected with bacteria, resulting in 
a marked reduction of bacterial killing. 
MATERIALS AND METHODS 
Cells and Reagents 
Animal procedures were approved by the Office Vétérinaire du 
Canton de Vaud (authorizations n° 876.6) and perfonned ac-
cording to institution guidelines for animal experiments. We 
purchased 8- to 10-week-old female BALB/c mice from Charles 
River Laboratories. We obtained mouse bone marrow-derived 
macrophages (BMDMs) and thioglycolate-elicited macrophages 
as previously described [10, 11]. RAW 264.7 macrophages were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 me-
dium containing 2 mmol/L glutamine and 10% fetal calf serum 
(FCS) [12]. E. coli 018:Kl:H7 (E. coli) and S. aureus AW7 
(S. aureus) are clinical isolates obtained from septic patients 
hospitalized at the Centre Hospitalier Universitaire Vaudois. We 
purchased trichostatin A (TSA) and val proie acid (VP A) from 
Sigma-Aldrich, Salmonella minnesota Ultra Pure lipopolysac-
charide (LPS) from List Biologicals Laboratories, and IFNy from 
R&D Systems. The concentrations ofTSA (dissolved in ethanol) 
and VPA (dissolved in phosphate-buffered saline [PBS]) used in 
this study were selected based on previous publications [13-18] 
and did not affect the viability (Trypan blue staining and 
3-[ 4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
[MTT] Cell Proliferation and Viability Assay) of BMDMs 
(;:::: 85% ce!! recovery after 18 hours of culture with 20-40 nmol/ 
L TSA and 1-2 mmol/L VPA with or without bacteria; n = 6-9 
determinations; P > .5 for all conditions). Ethanol and PBS ve-
hicle controls were performed in each experiment. For simplicity 
only 1 set of data is presented in each (Figures 2, 4, 5, and 6). 
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Assay for Bacterial Uptake and Bacterial Killing 
E. coli and S. aureus were grown overnight at 37°C in tryptic soy 
broth (BD Biosciences), washed in PBS, and adjusted to 107 
colony-forming units (CFU)/mL in RPMI medium containing 
10% FCS. BMDMs (4 X 105 cells in 24-well cell-culture plates, 
Costar) were treated with TSA or VPA for 18 hours. Medium 
was changed and cells were incubated for 1 hour with bacteria at 
a multiplicity of infection of 20 bacteria per macrophage. 
Nonadherent bacteria were removed by washing with PBS. Ex-
tracellular bacteria were killed by a 30-minute exposure to either 
100 µg/mL of gentamicin (E. coli) or 10 µg/mL of lysostaphin 
(S. aureus). We washed and lysed BMDMs. We plated serial 
dilutions of cell lysates on agar plates and enumerated colonies 
to calculate the number of phagocytosed bacteria. In parallel 
wells, BMDMs were treated as previously except that, after 30 
minutes of incubation with antibiotics, cells were washed and 
incubated for a further 24 hours in culture medium containing 
20 µg/mL gentamicin or 10 µg/mL lysostaphin. Bacteria were 
enumerated and results expressed as percent changes in bacterial 
counts using the following formula: (count after 24 hours/count 
after 1 hour) X 100. Of note, neither TSA nor VPA at the 
concentrations used in these assays were taxie for bacteria. 
RNA Analysis by Ouantitative Real-lime Polymerase Chain 
Reaction 
RNA was isolated using the RNeasy kit (Qiagen). Reverse tran-
scription was perfonned using the ImProm II RT System kit 
(Promega). Quantitative real-time polymerase chain reaction 
(PCR) was performed with a 7500 Fast Real-Time PCR System 
using the Power SYBR Green PCR Master Mix (Applied Bio-
systems) and primer pairs (Supplementaiy Table 1) as previously 
described [19]. We tested samples in triplicate. For each mea-
surement, we processed in parallel a standard made of successive 
dilutions of a reference complementary DNA. The relative ex-
pression levels of NADPH oxidase subunits and inducible nitric 
oxide synthase (iNOS) were reported to the relative expression of 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and ex-
pressed in arbitrary units (AU). The expression of phagocytic re-
ceptors and TLRs was calculated with the comparative Ct (L1L1Ct) 
method . The expression of the target gene was first normalized to 
the endogenous contra! (Gapdh) and then to that of a calibrator 
(ie, data obtained from cells cultured with vehicle set at 1). Im-
p01tantly, the Ct values of Gapdh were not affected by TSA or VP A 
(19.24 ± 0.13, 19.10 ± 0.03, 19.30 ± 0.48, 19.21 ± 0.06, and 19.10 
± 0.15 in BMDMs cultured for 18 hours with medium, 20 nmol/L 
TSA, 40 nmol/L TSA, 1 mmol/L VP A, and 2 mmol/L VP A, re-
spectively; n = 6 determinations; P > .05 for all conditions 
compared with cells cultured in medium). In selected experiments, 
results were validated using Hprt as an endogenous contra!. 
Flow Cytometric Analysis 
BMDMs cultured for 18 hours with TSA (40 nmol/L) and VPA 
(2 mmol/L) were incubated 30 minutes at 4 °C in PBS containing 
5% FCS, 5 mM ethylenediaminetetraacetic acid (EDTA), 2.4G2 
monoclonal antibody, and monoclonal antibodies specific for 
macrophage scavenger receptor 1 (Msrl/CD204), CDl le, CD14, 
and major histocompatibility complex II (MHC-II) [20]. Ac-
quisition and analysis were performed using a FACSCalibur (BD 
Biosciences) and FlowJo 8.5.3 software (FlowJow). 
Analysis of Oxidative Burst Using the Dichlorofluorescein 
Diacetate Fluorescence Assay 
BMDMs (4 X 105 cells in 24-well cell-culture plates) were 
cultured as previously described [21] and incubated for 18 hours 
with TSA and VPA. Dichlorofluorescein diacetate (DCFDA) 
(20 µmol/L, Sigma-Aldrich) was added to the cultures followed 
15 minutes later by bacteria (5 X 108 CFU/mL). After 30 mi-
nutes, cell fluorescence was measured by flow cytometry. 
Western Blot Analysis 
Cell lysates were electrophoresed through polyacrylamide gels 
and transferred onto nitrocellulose membranes as previously 
described [12]. Membranes were incubated with antibodies di-
rected against iNOS (BD Biosciences), p47phox (Santa Cruz) and 
tubulin (Sigma). After washing, membranes were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibody 
(Pierce). Signais were revealed using the ECL Western blotting 
analysis system (GE Healthcare). 
Nitrite/Nitrate Measurements 
BMDMs (105 cells in 96-well cell-culture plates) were pre-
incubated for 1 hour with TSA and VP A and stimulated with 
LPS (100 ng/mL), IFNy (100 U/mL), E. coli (108 CFU/mL), 
and S. aureus (108 CFU/mL). Cell-culture supernatants were 
collected after 24 hours. The concentrations of nitrite/nitrate 
were measured using the Griess reagent. 
Statistics 
Statistical analyses were performed using PRISM ( GraphPad 
Software). Comparisons between the different groups were 
performed by analysis of variance and appropriate post hoc 
analyses. P values are 2-sided, and values of < .05 were con-
sidered to indicate statistical significance. 
RESULTS 
HDACi lnhibit Bacterial Phagocytosis by Macrophages 
We recently reported that HDACi impair hast defenses to 
bacterial infection in vivo [9]. Whether HDACi impact the 
phagocytosis and the killing of bacteria is currently unknown. 
To fill this gap, we first analyzed the phagocytosis of gram-
negative (E. coli) and gram-positive (S. aureus) bacteria by 
BMDMs pretreated with 2 chemically unrelated HDACi: TSA, 
a hydroxamate widely used as a prototypical broad-spectrum 
HDACi, and VPA, a clinically relevant short fatty acid. The dose 
and duration of treatment with TSA and VP A were in the range 
of those used in cancer preclinical studies or measured in pa-
tients enrolled in cancer clinical trials (VP A) (see for example 
[13-18]). We evaluated phagocytosis after 1 hour of contact 
between bacteria and macrophages. As shown in Figure 1, 
HDACi dose dependently reduced the number of E. coli (2- to 
4-fold; P < .05) and S. aureus (1.5- to 2-fold; P < .05) phago-
cytosed by BMDMs. 
HDACi Impair the Expression of Phagocytic Receptors 
Macrophages express phagocytic scavenger receptors, including 
macrophage scavenger receptor 1 (Msrl/SR-AI/CD204), CD14, 
CD36, and C-type lectins such as Dectin-1 (encoded by Clec7a) 
that mediate the recognition of microbial ligands expressed at 
the surface of pathogens and initiate phagocytosis. Macrophages 
also express opsonic phagocytic receptors of the integrin family 
(integrinœx/Itgax/CD 11 c, integrin132/Itgb2/CD 18, and integrinœ5/ 
Itga5/CD49e) that facilitate the uptake of microorganisms 
coated with opsonins lilœ the mannose-binding lectin, comple-
ment subcomponents, growth arrest specific 6, ficolins, and 
pentraxins [2, 22]. TSA and VPA reduced 2- to 10-fold Msrl, 
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Figure 1. Histone deacetylase inhibitors impair the phagocytosis of 
Escherichia co!i(A) and Staphy!ococcus aureus(B). Mause bone marro~­
derived macrophages (BMDMs) were incubated for 18. hou~s w1th 
increasing concentrations of trichostatin A (TSA) and valpro1c ac1d (~PA) 
before the addition of 1 o7 colony-forming units (CFU) of E colt or 
1.5 x 101 CFU of s. aureus. The number of bacteria ingested by BMDMs 
was determined 1 hour later. Data are presented a.s mean ± stand~rd 
deviation (SD) of quadruplicate samples ~r2~ 1 expenment representat1ve 
of 2-3 experiments. *, .05 < P < .005, ' p < .oo5. 
CD14, Dectin-1 and Itgax: messenger RNA (mRNA) levels in 
BMDMs (Figure 2A). TSA inhibited Itgb2 expression more ef-
ficientlythan did VPA (2.4-fold with 40 nM TSA vs 1.4-fold with 
2 mM VPA), whereas HDACi did not affect CD36, Itga5, or 
Itga6 expression. Flow cytometry analyses confirmed that TSA 
and VPA inhibited the expression ofMsrl, CDllc and CD14 by 
BMDMs (Figure 2B). As a control of nonspecific broad in-
hibitory effects of HDACi, MHC-II expression was not affected 
by HDACi. Ali together, these data suggest that reduced ex-
pression of phagocytic receptors may contribute to impair the 
phagocytosis of B. coli and S. aureus in macrophages treated with 
HD A Ci. 
HDACi lnhibit Bacterial Killing 
TLRs play crucial roles in the sensing of invasive microorganisms 
and in transmitting signals involved in the maturation of phag-
osomes [23]. Interestingly, we observed that HDACi strongly 
reduced baseline expression of TLRl-7 and TLR9 in BMDMs 
(Figure 2C). Pathogen delivery to phagolysosomes usually results 
in effective microbial killing [2, 24]. In agreement,< 5% of B. coli 
and 25% of S. aureus phagocytosed by BMDMs were recovered 
24 hours later in macrophages (P < .001; Figure 3). TSA and 
VPA reduced 5-fold and 3-fold E. coli and S. aureus killing, re-
spectively (ie, increasing bacteria recove1y to 25% and 75% of the 
ingested inoculum; P < .05). Thus, HDACi inhibit bath the 
phagocytosis (Figure 1) and the killing (Figure 3) of bacteria by 
macrophages, in agreement with the observation that HDACi 
increased the susceptibility of mice to microbial infection [ 9]. 
HDACi lnterfere With the Generation of Reactive Oxygen 
Species 
In response to microbial challenge, macrophages produce highly 
toxic reactive oxygen species (ROS) that contribute to pathogen 
destruction [25]. The generation of ROS in BMDMs was ana-
lyzed by flow cytometry using the cell permeable nonfluorescent 
dye 2' ,7' -dichlorofluorescein diacetate (DCFDA) that is trans-
formed on oxidation into the highly fluorescent DCF. B. coli and 
S. aureus strongly increased DCF fluorescence in BMDMs, 
which was inhibited 2- to 3-fold by TSA or VPA (Figure 4A and 
4B). HDACi also inhibited the production of ROS in BMDMs 
stimulated with phorbol myristate acetate (> 10-fold reduction, 
data not shown) indicating that HDACi inhibit the oxidative 
burst induced by microbial and nonmicrobial stimuli. 
In macrophages, ROS are generated during the respiratory 
burst through the action of the phagocytic NADPH oxidase, 
an enzymatic complex composed of 2 membrane-associated 
subunits (gp9lphox/NOX2 and p22phox), 3 cytosolic subunits 
( 47phox 40phox d 6 phox) d h · p , p , an p 7 , an t e Rac2 regulatory subumt 
[26, 27]. Cytokines, particularly IFNy, and microbial products 
released during an infection prime and amplify macrophage 
respiratory burst through the induction of NADPH oxidase 
subunits [21]. Real-time PCR and Western blot analyses re-
vealed that TSA and VP A dose-dependently inhibited baseline 
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Figure 2. Histone deacetylase inhibitors inhibit the expression of 
phagocytic and Toll-like receptors. A, Real-time polymerase chain reaction 
(PCR) analysis of Msr1, CD14, CD36, Clec7a, ltgax, ltgb2, ltga5, and ltga6 
messenger RNA expression in mouse bone marrow-derived macrophages 
(BMDMs) incubated for 8 hours with increasing concentrations of 
trichostatin A (TSA) and valproic acid (VPA). Data are presented as 
mean ± standard deviation (SD) of triplicate samples from 1 experiment and 
are representative of 2 independent experiments. 8, Flow cytometry analysis 
of Msr1, CD14, CD11c, and major histocompatibility complex Il (MHC-11) 
expression by BMDMs incubated for 18 hours with medium (gray area), TSA 
(dashed fine), and VPA (sofid fine). Results are representative of 2 
îndependent experîments. C, Real-time PCR analysîs of Toll-like receptors in 
BMDMs incubated for 8 hours with increasing concentrations of TSA and 
VPA. Data are presented as mean ± standard deviation (SD) of triplicate 
samples from 1 experiment and are representative of 2 independent 
experiments. AU, arbitrary units; *, .05 < P < .005; **, P < .005. 
expression of NAD PH oxidase subunits and potently inhibited 
the upregulation of the catalytic gp91 phox and regulatory p47phox 
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Figure 3. Histone deacetylase inhîbitors impair the killîng of 
Escherichia cofi and Staphyfococcus aureus. Mause bone marrow-
derived macrophages (BMDMs) were cultured for 18 hours with 
increasing concentrations of trichostatin A (TSA) and valproic acid 
(VPA) before the addition of 107 colony-forming units (CFU) of E. cofi (A) or 
1.5 x 107 CFU of S. aureus (8). The number of bacteria recovered from 
macrophages after 24 hours was divided by the number of bacteria 
recovered after 1 hour and expressed in percentage using the formula 
(cou nt after 24 hours/count after 1 hour) X 1 OO. Data are presented as 
mean ± standard deviation (SD) of quadruplicate samples from 1 
experiment representative of 2-3 experiments. *, .05 < P < .005; 
**, p < .005. 
subunits in LPS+ IFNy-stimulated macrophages (Figure 5). Ali 
together, these data provide compelling evidence that HDACi 
inhibit ROS production in macrophages. 
HDACi lnhibit Nitric Oxide Production and iNos Gene 
Expression 
Nitric oxide (NO) is produced during the nitrosative burst by 
iNOS and represents an important antimicrobial effector 
mechanism [25, 27]. TSA and VPA dose-dependently inhibited 
the production of NO by BMDMs stimulated with LPS+ IFNy 
(50%-80% reduction; P < .05), in line with previous work 
showing that HDACi inhibit cytokine-induced NO release 
[28, 29]. More relevant for microbial infection, TSA and to 
a lesser extent VPA inhibited NO production induced by E. coli 
and S. aureus (50%-60% reduction using 20 nmol/L and 40 
nmol/L TSA and 30%-35% reduction using 2 mmol/L VPA; 
P < .05) (Figure 6A). In agreement with these findings, real-time 
PCR and Western blot analyses demonstrated that TSA and VP A 
inhibited iNOS mRNA and protein expression in BMDMs 
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Figure 4. Histone deacetylase inhibîtors interfere with the generation 
of reactive oxygen species. Mouse bone marrow-derived macrophages 
(BMDMs) were incubated with trichostatin A (TSA; 40 nmol/L) and 
valproic acid (VPA; 2 mmol/L) and exposed to Escherichia cofi or 
Staphyfococcus aureus as described in Material and Methods. A, The 
generation of reactive oxygen species (ROS) was quantified by flow 
cytometry by measuring dichlorofluorescein (DCF) diacetate oxidation into 
fluorescent DCF. 8, Data are means ± standard deviation (SD) of 2 
independent determinations. P = .03 and .008 for E. cofi and S. aureus vs 
contrai. *, P = .05; **, .05 < P < .005 vs E. cofi-- and S. aureus-treated 
ce lis. 
(Figure 6B and 6C). Similar results were obtained using thio-
glycolate-elicited peritoneal and RA W 264. 7 macrophages (data 
not shown). Taken together, these results suggest that HDACi 
impair NO production by BMDMs in response to bacterial 
challenge by interfering with iNOS expression. 
DISCUSSION 
In this study, we report for the first time to our knowledge that 
HDACi inhibit the phagocytosis and the killing of bacteria, the 
expression of phagocytic receptors, and the generation of oxi-
dative and nitrosative bursts induced by bacteria in macro-
phages. These data extend our previous work demonstrating 
that HD A Ci interfere with cytokine production by macrophages 
and impair host defenses to bacterial infection [9}. 
The inhibition of E. coli and S. aureus phagocytosis by 
HDACi was associated with a reduced expression of phago-
cytic receptors, among which is Msrl (scavenger receptor Al). 
Msrl binds a wide range of microbial ligands and mediates 
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Figure 5. Histone deacetylase inhibitors inhibit nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase subunits expression. A. Real-time 
polymerase chain reaction (PCR) analysis of gp91, p22, p47, p67, p40, and 
Rac2 messenger RNA expression in mouse bone marrow--derived macro-
phages (BMDMs) cultured for 8 hours with trichostatin A (TSA) and valproic 
acid (VPA). Results are expressed as the ratio of the gene of interest to that of 
glyceraldehyde-3-phosphate dehydrogenase. Real-time PCR (8) and 
Western blot ( C) analyses of gp91 and p47 expression in BMDMs 
cultured for 1 hour with TSA and VPA and then stimulated for 6 hours with 
lipopolysaccharide (LPS; 1 OO ng/ml) + interferon y (IFNy; 1 OO U/ml). Data 
are presented as means ± standard deviation (SD) of triplicate samples 
from 1 experiment and are representative of 2 independent experiments 
(A, 8). Abbreviation: AU, arbitary units.*, P < .005 vs contrai (A) and 
LPS+IFNy (8). 
nonopsonic phagocytosis of B. coli and S. aureus [30]. 
Moreover, Msrl _1_ mice are more susceptible than wild-type 
mice to S. aureus infection [31]. Thus, HDACi-mediated in-
hibition of Msrl expression may well help impair bacterial 
phagocytosis, although HDACi may target other phagocytic 
receptors such as the mannose receptor, MARCO, or CD14. 
Of note, HDACi decreased Dectin-1 expression in BMDMs. 
Considering that Dectin-1 is a major receptor involved in the 
recognition of P-glucan, we speculate that HDACi may affect 
the phagocytosis of yeast. In line with this hypothesis, we 
observed that VP A increases mortality of mice infected with 
Candida albicans [ 9]. 
The rtx and p2 integrin subunits contribute to the structure of 
complement receptor (CR) 3 and CR4 that mediate the recog-
nition of opsonized microorganisms by phagocytes. p2 integrins 
play an important role in antimicrobial defenses as suggested by 
the observation that patients with leukocyte adhesion deficiency 
type I (LADI) syndrome (ie, patients deficient in functional p2 
integrin) have defects in phagocytosis and are proue to bacterial 
infections [32]. Ali together, inhibition of the expression of rtx 
and p2 integrins and scavenger and lectin receptors by HDACi 
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Figure 6. Histone deacetylase inhibitors impair nitric oxide production and 
iNos gene expression. Mouse bone marrow--derived macrophages (BMDMs) 
were cultured for 1 hour with trichostatin A (TSA) and valproic acid (VPA) 
and then stimulated with lipopolysaccharide + interferon y (100 ng/ml and 
1 OO U/ml), Escherichia co!i (10 8 colony-forming units [CFU}lmL}, and 
Staphy!ococcus aureus (108 CFU/ml) for 24 hours (A) or 8 hours (8-C). 
A. Nitrite/nitrate concentration in cell culture supernatants was measured 
using the Griess reagent. Data are presented as mean ± standard deviation 
(SD) of triplicate samples from 1 experiment and are representative of 
4 independent experiments. Real-time polymerase chain reaction (PCR) (8) 
and Western blot ( C) analyses of inducible nitric oxide synthase (iNOS) 
expression. Results are expressed as the ratio of iNOS mRNA levels ta that 
of glyceraldehyde-3-phosphate dehydrogenase. Data are means ± SD of 
triplicate samples from 1 experiment and are representative of 3 independent 
experiments. Abbreviation: AU, arbitrary units. *, .05 < P < .005; ** 
P< .005. 
support the contention that HDACi interfere with bacterial 
opsonic and nonopsonic phagocytosis. 
HD A Ci powerfully inhibited the killing of B. coli and S. aureus 
by macrophages. This observation is congruent with the fact that 
VP A treatment increased the proportion and the magnitude of 
bloodstream infections in mice infected with Klebsiella pneu-
moniae [9]. Reaètive oxygen and nitrogen species are among the 
most deleterious components produced by phagocytes and 
implicated in the destruction of microorganisms [ 2, 24]. De-
ficiency in members of the NADPH oxidase complex or in 
iNOS, which control the generation of superoxide (02 -
0
) and 
nitric oxide (N0°) radicals, impair the killing of B. coli and 
S. aureus by innate immune cells and compromise mouse 
survival [33-36]. Moreover, germ-line mutation in 1 of the 
components of NADPH oxidase complex results in chronic 
granulomatous disease characterized by recurrent bact.e~i~l and 
fungal infections and reduced life expectancy [25]. Inh1bit10n of 
NADPH oxidase subunit and iNOS expression and of reactive 
oxygen and nitrogen species generation by HDACi likely rep-
resents an effective mechanism by which these drugs impair the 
killing of bacteria. 
In agreement with the notion that phagocytosis is coupled 
with a proinflammatory cytokine response and with the obser-
vation that HDACi inhibit TLR expression, HDACi strongly 
impaired the secretion of cytokines and chemokines (TNF, IL-6, 
IL-12p40, and MIP-2rt, data not shown) by macrophages in-
fected with B. coli and S. aureus. These data expand on recent 
studies showing that HDACi inhibit cytokine production in-
duced by cytokines and purified microbial products in innate 
immune cells [14, 15, 28, 37, 38]. Considering that proin-
flammatory media tors released during the course of an infection 
coordinate the development of innate and adaptive immunity, 
one may expect that HDACi interfere with the generation of 
pathogen-specific adaptive immune response. 
HDACi have been reported to interfere with signaling path-
ways controlling the expression of genes particularly relevant for 
this study. Indeed, HDACi down-regulate the expression of 
PU.l transcription factor [37, 39], which regulates constitutive 
expression of HDACi-target genes encoding for integrins, 
scavenger receptors, TLR4, CD14, and p40, p47, and p67 
NADPH oxidase subunits [20, 40]. Moreover, HDACi have been 
reported to interfere with the activation of mitogen-activated 
protein kinases, NF-KB, and AP-1, which control inflammatory 
and antimicrobial host responses [15, 41]. HDACi also impair 
gene expression through chromatin modifications or aceytlation-
dependent recruitment of transcriptional repressors, albeit these 
mechanisms are less well characterized. For example, TSA in-
hibits the expression of the proinflammatory cytokine macro-
phage migration inhibito1y factor through a local deacetylation 
of migration inhibitmy factor-promoter-associated histones 
impairing the recruitment of the basal transcriptional machinery 
[42, 43]. Finally, we have recently shown that TSA inhibits 
macrophage response to LPS stimulation by inducing the ex-
pression of Mi-2P and the activity of the Mi-2/NuRD tran-
scriptional repressor complex [9]. 
HDACi have been used to treat inflammatory diseases in 
mouse models [8]. Abundant preclinical and clinical studies 
indicate that interfering with critical mediators of innate or 
adaptive immunity increases the risk of infections. Thus, one 
may question whether HD A Ci might affect natural host defenses 
in patients, as could be anticipated from the powerful immu-
nomodulat01y and anti-inflammatory activities of HDACi in 
vivo [8] and the increased susceptibility to bacterial and fungal 
infections of mice treated with HDACi [9]. Patients treated with 
HDACi (suberoylanilide hydroxamic acid, MS-275, valproate, 
and ITF2357) in phase I and II clinical trials have developed 
episodes of severe infection even in the absence of treatment-
induced neutropenia [ 44-49], suggesting the need to monitor 
the immune status and susceptibility to infection of patients 
treated with HDACi, especially immunosuppressed cancer 
patients [4-6, 50]. 
In summary, this study demonstrates that HDACi impair the 
capacity of macrophages to ingest and destroy gram-positive 
and gram-negative bacteria. The fact that HDACi impede the 
expression of phagocytic receptors, the generation of oxygen-
and nitrogen-reactive species, and the release of proin-
flammatory cytokines provide a plausible mechanism whereby 
HDACi negatively impact critical antimicrobial fonctions of 
innate immune cells and increase the susceptibility of mice to 
bacterial and fungal infection [9]. 
Supplementary Data 
Supplementary data are available at The Journal of infections Diseases 
online (http://www.oxfordjournals.org/our_journals/jid/). 
Supplementaty materials consist of data provided by the author that are 
published to benefit the reader. The posted materials are not copyedited. The 
contents of ail supplementary data are the sole responsibility of the authors. 
Questions or messages regarding errors should be addressed to the author. 
Notes 
Fi11a11cial support. This work was supported by the Swiss National 
Science Foundation (310000_114073 and 310030_132744 to T. R. and 
310000 118266 to T. C.); a Merck Sharp & Dohme-Chibret award from 
the Sw~s Society for Infectious Diseases; and the Leenaards Foundation 
(to T. R.). 
Potential conflicts of interest. Ali authors: No reported conflicts. 
Ali authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the 
content of the manuscript have been disclosed. 
References 
1. Ishii KJ, Koyama S, Nakagawa A, Cohan C, Akira S. Host innate im-
mune receptors and beyond: Making sense of microbial infections. Cell 
Host Microbe 2008; 3:352-63. 
2. Stuart LM, Ezekowitz RA. Phagocytosis: Elegant complexity. Immunity 
2005; 22:539-50. 
3. Flannagan RS, Cosio G, Grinstein S. Antimicrobial mechanisms of 
phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009; 
7:355-66. 
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone 
deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84. 
5. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 
26:5420-32. 
6. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise 
of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 
6:38-51. 
7. Yang XJ, Seto E. The Rpd3/Hdal family of lysine deacetylas~s: From 
bacteria and yeast to mice and men. Nat Rev Mol Cell B10l 2008; 
9:206-18. 
8. Haberland M, Montgomery RL, Oison EN. The many raies of histone 
deacetylases in development and physiology: Implications for disease 
and therapy. Nat Rev Genet 2009; 10:32-42. 
HDACi Impair Macrophage Functions • JID 2011:204 (1 November) • 1373 
9. Roger T, Lugrin J, Le RD, et al. Histone deacetylase inhibitors impair 
innate immune responses to Toll-like receptor agonists and to in-
fection. Blood 2011; 117:1205-17. 
10. Roger T, Froidevaux C, Le RD, et al. Protection from lethal gram-
negative bacterial sepsis by targeting Toll-like receptor 4. Proc Nat! 
Acad Sei U S A 2009; 106:2348-52. 
Il. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate im-
mune responses through modulation of Toll-like receptor 4. Nature 
2001; 414:920-4. 
12. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage 
migration inhibitory factor promotes innate immune responses by 
suppressing glucocorticoid-induced expression of mitogen-activated 
protein kinase phosphatase-1. Eur J lmmunol 2005; 35:3405-13. 
13. Atmaca A, Al-Batran SE, Maurer A, et al. Valproic acid (VPA) in 
patients with refractory advanced cancer: A dose escalating phase 1 
clinical trial. Br J Cancer 2007; 97: 177-82. 
14. Bode KA, Schroder K, Hume DA, et al. Histone deacetylase inhibitors 
decrease Toll-like receptor-mediated activation of proinflammato1y 
gene expression by impairing transcription factor recruitment. Im-
munology 2007; 122:596-606. 
15. Cao W, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogen-
activated protein kinase phosphatase-1 inhibits Toll-like receptor sig-
naling. J Exp Med 2008; 205:1491-503. 
16. Daud Al, Dawson J, DeConti RC, et al. Potentiation of a topoisomerase 
1 inhibitor, karenitecin, by the histone deacetylase inhibitor valproic 
acid in melanoma: Translational and phase !/Il clinical trial. Clin 
Cancer Res 2009; 15:2479-87. 
17. Münster P, Marchion D, Bicaku E, et al. Phase 1 trial of histone de-
acetylase inhibition by valproic acid followed by the topoisomerase II 
inhibitor epirubiein in advanced solid tumors: A clinical and trans-
lational study. J Clin Oncol 2007; 25:1979-85. 
18. Münster P, Marchion D, Bicaku E, et al. Clinical and biological effects 
of val proie aeid as a histone deacetylase inhibitor on tumor and sur-
rogate tissues: Phase !/Il trial of valproic acid and epirubiein/FEC. Clin 
Cancer Res 2009; 15:2488-96. 
19. Delaloye J, Roger T, Steiner-Tardive! QG, et al. Innate immune sensing 
of modified vaceinia \~rus Ankara (MVA) is mediated by TLR2-TLR6, 
MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5:el000480. 
20. Roger T, Miconnet !, Schiesser AL, Kai H, Miyake K, Calandra T. 
Critical role for Ets, AP-1 and GATA-like transcription factors in 
regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem 
J 2005; 387:355-65. 
21. Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic 
NADPH oxidase by indueing the expression of gp9Iphox. J Bio! Chem 
2006; 281:5657-67. 
22. Areschoug T, Gordon S. Scavenger receptors: Role in innate immunity 
and microbial pathogenesis. Cell Microbiol 2009; 11:1160-9. 
23. Blander JM. Signalling and phagocytosis in the orchestration of hast 
defence. Cel! Microbiol 2007; 9:290-9. 
24. Underhill DM, Ozinsky A. Phagocytosis of microbes: Complexity in 
action. Annu Rev Immunol 2002; 20:825-52. 
25. Fang FC. Antimicrobial reactive oxygen and nitrogen species: Concepts 
and controversies. Nat Rev Microbiol 2004; 2:820-32. 
26. Bedard K, Krause KH. The NOX family of ROS-generating NADPH 
oxidases: Physiology and pathophysiology. Physiol Rev 2007; 87:245-313. 
27. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev 
Immunol 2004; 4:181-9. 
28. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase 
inhibitor suberoylanilide hydroxamic aeid exhibits antiinflammatory 
properties via suppression of cytokines. Proc Nat! Acad Sei US A 2002; 
99:2995-3000. 
29. Reilly CM, Mishra N, Miller JM, et al. Modulation of renal disease in 
MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 
173:4171-8. 
1374 • JID 2011:204 (1 November) • Mombelli et al 
30. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate 
immunity. Curr Opin lmmunol 2002; 14:123-8. 
31. Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J. 
Protection from lethal gram-positive infection by macrophage 
scavenger receptor-dependent phagocytosis. J Exp Med 2000; 
191:147-56. 
32. Bunting M, Harris ES, Mcintyre TM, Prescott SM, Zimmerman GA. 
Leukocyte adhesion defieiency syndromes: adhesion and tethering 
defects involving beta 2 integrins and selectin ligands. Curr Opin 
Hematol 2002; 9:30-5. 
33. Shiloh MU, MacMicking JD, Nicholson S, et al. Phenotype of mice and 
macrophages defieient in bath phagocyte oxidase and indueible nitric 
oxide synthase. Immunity 1999; 10:29-38. 
34. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out 
mode! of chronic granulomatous disease. J Exp Med 1995; 182:751-8. 
35. Ellson CD, Davidson K, Ferguson GJ, O'Connor R, Stephens LR, 
Hawkins PT. Neutrophils from p40phox-/- mice exhibit severe defects 
in NADPH oxidase regulation and oxidant-dependent bacterial killing. 
J Exp Med 2006; 203:1927-37. 
36. Sasaki S, Miura T, Nishikawa S, Yamada K, Hirasue M, Nakane A. 
Protective raie of nitric oxide in Staphylococcus aureus infection in 
mice. Infect Immun 1998; 66:1017-22. 
37. Aung HT, Schroder K, Himes SR, et al. LPS regulates proinflammat01y 
gene expression in macrophages by altering histone deacetylase ex-
pression. FASEB J 2006; 20:1315-27. 
38. Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are 
required for innate immune cell contrai of Th! but not Th2 effector cell 
function. Blood 2007; 109:1123-30. 
39. Laribee RN, Klemsz MJ. Lass of PU.1 éxpression following inhibition 
of histone deacetylases. J lmmunol 2001; 167:5160-6. 
40. Gallant S, Gilkeson G. ETS transcription factors and regulation of 
immunity. Arch Immunol Ther Exp (Warsz) 2006; 54:149-63. 
41. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive raie 
of histone acetyltransferases and deacetylases in an NF-kappaB-
signaling code. Trends Biochem Sei 2008; 33:339-49. 
42. Calandra T, Roger T. Macrophage migration inhibito1y factor: a regu-
lator of innate immunity. Nat Rev Immunol 2003; 3:791-800. 
43. Lugrin J, Ding XC, Le Roy D, et al. Histone deacetylase inhibitors 
repress macrophage migration inhibitory factor (MIF) expression by 
targeting MIF gene transcription through a local chromatin deacety-
lation. Biochim Biophys Acta 2009; 1793:1749-58. 
44. Ryan QC, Headlee D, Acha1ya M, et al. Phase 1 and pharmacokinetic study 
of MS-275, a histone deacetylase inhibitor, in patients with advanced and 
refractory solid tumors or lyn1phoma. J Clin Oncol 2005; 23:3912-22. 
45. Kelly WK, O'Connor OA, Krug LM, et al. Phase 1 study of an oral 
histone deacetylase inhibitor, suberoylanilide hydroxamic aeid, in pa-
tients with advanced cancer. J Clin Oncol 2005; 23:3923-31. 
46. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologie study of 
MS-275, a histone deacetylase inhibitor, in adults with refractory and 
relapsed acute leukemias. Blood 2007; 109:2781-90. 
47. Candelaria M, Gallardo-Rinc6n D, Arce C, et al. A phase II study of 
epigenetic therapy with hydralazine and magnesium valproate to 
overcome chemotherapy resistance in refractory solid tumors. Ann 
Oncol 2007; 18:1529-38. 
48. Rocca A, Minucei S, Tosti G, et al. A phase !-II study of the histone 
deacetylase inhibitor valproic acid plus chemoimmunotherapy in pa-
tients with advanced melanoma. Br J Cancer 2009; 100:28-36. 
49. Galli M, Salmoiraghi S, Golay J, et al. A phase II multiple dose 
clinical trial of histone deacetylase inhibitor ITF2357 in patients with 
relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 
185-90. 
50. Song W, Tai YT, Tian Z, et al. HDAC inhibition by LBH589 affects the 
phenotype and function of human myeloid dendritic cells. Leukemia 
2011; 25:161-8. 
